来氟米特和环磷酰胺静脉冲击疗法治疗狼疮性肾炎的疗效分析

马世兴

（宝鸡市中心医院，陕西 宝鸡，721008）

浏览次数：73次 下载次数：598次

摘要：

目的 比较来氟米特和环磷酰胺静脉冲击疗法治疗狼疮性肾炎的疗效。方法 选择我院收治的86例狼疮性肾炎患者， 依照就诊顺序将其分为观察组和对照组，每组43例。对照组在常规治疗基础上接受环磷酰胺静脉冲击治疗，观察组在常规治疗基础上接受来氟米特治疗，比较两组患者的治疗效果。结果 治疗前，两组患者红斑狼疮DAI 分数、C3 补体、抗ds-DNA 抗体及24 h 蛋白尿指标比较，差异无统计学意义（P>0.05）；治疗3个月和6个月时，两组患者上述指标均有所改善，差异有统计学意义（P<0.05），但组间数据无显著差异（P>0.05）。对照组总缓解率为67.44%，观察组为72.09%，差异无统计学意义（P>0.05）。观察组不良反应发生率为6.98%，明显低于对照组的23.26%（P<0.05）。结论 对狼疮性肾炎患者使用来氟米特进行治疗，可以在保证治疗效果的同时，确保患者用药安全，值得进一步推广。

关键词：来氟米特；环磷酰胺；静脉冲击疗法；狼疮性肾炎

中图分类号：R593.242文献标志码：A文章编号：2096-1413(2017)19-0039-02

Efficacy analysis of leflunomide and cyclophosphamide intravenous therapy in the treatment of lupus nephritis
MA Shi-xing
(Baoji Central Hospital, Baoji 721008, China)

ABSTRACT: Objective To compare the effects of leflunomide and cyclophosphamide intravenous therapy in the treatment of lupus nephritis. Methods A total of 86 patients with lupus nephritis in our hospital were selected and divided into observation group and control group according to the visiting sequence, with 43 cases in each group. The control group was treated with cyclophosphamide intravenous therapy on the basis of conventional therapy, while the observation group was treated with leflunomide on the basis of conventional treatment, and the therapeutic effects were compared between the two groups. Results Before treatment, there were no significant differences in lupus erythematosus DAI scores, C3 complement, anti-ds-DNA antibody and 24 h proteinuria between the two groups (P>0.05). In 3 months and 6 months after treatment, the above indicators in the two groups improved (P<0.05), but there were no significant differences of the above indicators between the two groups (P>0.05). The total remission rate was 67.44% in the control group and 72.09% in the observation group, and there was no significant difference between the two groups (P>0.05). The adverse reaction rate was 6.98% in the observation group, which was significantly lower than 23.26% in the control group (P<0.05). Conclusion For patients with lupus nephritis, leflunomide for treatment can ensure the effectiveness of treatment and the medication safety of patients, which is worthy of further promotion.
KEYWORDS: leflunomide; cyclophosphamide; intravenous therapy; lupus nephritis

参考文献：
[1] 何华妮.来氟米特联合吗替麦考酚酯与环磷酰胺冲击治疗狼疮性肾炎患者有效性和安全性比较[J].国际泌尿系统杂志,2015,35(5):739-743.
[2] 吕卫,吕锋.免疫抑制剂联合小剂量糖皮质激素三联疗法治疗狼疮性肾炎疗效分析[J].海南医学,2016,27(12):2009-2011.
[3] 杜艳彬,杨岳,白亚君,等.来氟米特与环磷酰胺对难治性肾患者凝血机制的影响[J].血栓与止血学,2016,22(2):161-164.
[4] 张彦芬,李涛,郭永力,等.来氟米特治疗狼疮性肾炎的临床疗效与安全性[J].西部医学,2015,27(6):861-864.
[5] 耿坡.来氟米特、环磷酰胺联合糖皮质激素对系统性红斑狼疮患者肾功能与免疫功能的影响[J].中国医药导刊,2016,18(5):506-507.
[6] 刘书真,谢泉琨,党勇.环磷酰胺、来氟米特联合泼尼松序贯疗法用于Ⅱ期膜性肾病的临床观察[J].中国药房,2016,27(15):2040-2042.